Circulating miR-378 in plasma: A reliable, haemolysis-independent biomarker for colorectal cancer

British Journal of Cancer

Volumn 110, Issue 4, 2014, Pages 1001-1007

  Zanutto, S ^a,b   Pizzamiglio, S ^a   Ghilotti, M ^a,b   Bertan, C ^a   Ravagnani, F ^a   Perrone, F ^a   Leo, E ^a   Pilotti, S ^a   Verderio, P ^a   Gariboldi, M ^a,b   Pierotti, M A ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COLORECTAL NEOPLASMS; HEMOGLOBINS; HEMOLYSIS; HUMANS; MICRORNAS; NEOPLASM RECURRENCE, LOCAL; TUMOR MARKERS, BIOLOGICAL;

EID: 84894354513     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.819     Document Type: Article

References (44)

1. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, Tait JF, Tewari M (2011) Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 108(12): 5003-5008.
2. Burch JA, Soares-Weiser K, John DJS, Duffy S, Smith S, Kleijnen J, Westwood M (2007) Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: A systematic review. J Med Screen 14: 132-137.
3. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6(11): 857-866.
4. Center MM, Jemal A, Smith RA, Ward E (2009) Worldwide variations in colorectal cancer. CA Cancer J Clin 59(6): 366-378.
5. Chang KH, Mestdagh P, Vandesompele J, Kerin MJ, Miller N (2010) MicroRNA expression profiling to identify and validate reference genes for relative quantification in colorectal cancer. BMC Cancer 10: 173.
6. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Zen K, Zhang CY (2008) Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18(10): 997-1006.
7. Chow TF, Mankaruos M, Scorilas A, Youssef Y, Girgis A, Mossad S, Metias S, Rofael Y, Honey RJ, Stewart R, Pace KT, Yousef GM (2010) The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. J Urol 183(2): 743-751.
8. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA (2011) MicroRNAs in body fluids-The mix of hormones and biomarkers. Nat Rev Clin Oncol 8(8): 467-477.
9. Dukes C (1932) The classification of cancer of the rectum. J Pathol Bacteriol 35: 323.
10. Faltejskova P, Bocanek O, Sachlova M, Svoboda M, Kiss I, Vyzula R, Slaby O (2012) Circulating miR-17-3p, miR-29a, miR-92a and miR-135b in serum: Evidence against their usage as biomarkers in colorectal cancer. Cancer Biomark 12(4): 199-204.
11. Feng M, Li Z, Aau M, Wong CH, Yang X, Yu Q (2011) Myc/miR-378/TOB2/cyclin D1 functional module regulates oncogenic transformation. Oncogene 30(19): 2242-2251.
12. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12): 2893-2917.
13. Filipowicz W, Bhattacharyya SN, Sonenberg N (2008) Mechanisms of post-Transcriptional regulation by microRNAs: Are the answers in sight? Nat Rev Genet 9(2): 102-114.
14. Frattini M, Gallino G, Signoroni S, Balestra D, Lusa L, Battaglia L, Sozzi G, Bertario L, Leo E, Pilotti S, Pierotti MA (2008) Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. Cancer Lett 263(2): 170-181.
15. Gellad ZF, Provenzale D (2010) Colorectal cancer: National and international perspective on the burden of disease and public health impact. Gastroenterology 138(6): 2177-2190.
16. Harrell Jr. FE, Califf RM, Pryor DB, Lee KL, Rosati RA (1982) Evaluating the yield of medical tests. JAMA 247(18): 2543-2546.
17. Hosmer D, Lemeshow S (1989) Applied Logistic Regression. Vol. 10, John Wiley & Sons: New York, NY, USA.
18. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X (2010) Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 127(1): 118-126.
19. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2): 69-90.
20. Kanaan Z, Rai SN, Eichenberger MR, Roberts H, Keskey B, Pan J, Galandiuk S (2012) Plasma miR-21: A potential diagnostic marker of colorectal cancer. Ann Surg 256(3): 544-551.
21. Kirschner MB, Edelman JJ, Kao SC, Vallely MP, van Zandwijk N, Reid G (2013) The Impact of Hemolysis on Cell-Free microRNA Biomarkers. Front Genet 4: 94.
22. Kirschner MB, Kao SC, Edelman JJ, Armstrong NJ, Vallely MP, van Zandwijk N, Reid G (2011) Haemolysis during sample preparation alters microRNA content of plasma. PLoS One 6(9): E24145.
23. Kosaka N, Iguchi H, Ochiya T (2010) Circulating microRNA in body fluid: A new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 101(10): 2087-2092.
24. Kulda V, Pesta M, Topolcan O, Liska V, Treska V, Sutnar A, Rupert K, Ludvikova M, Babuska V, Holubec Jr. L, Cerny R (2010) Relevance of miR-21 and miR-143 expression in tissue samples of colorectal carcinoma and its liver metastases. Cancer Genet Cytogenet 200(2): 154-160.
25. Lange CP, Campan M, Hinoue T, Schmitz RF, Van Der Meulen-de Jong AE, Slingerland H, Kok PJ, Van Dijk CM, Weisenberger DJ, Shen H, Tollenaar RA, Laird PW (2012) Genome-scale discovery of DNA-methylation biomarkers for blood-based detection of colorectal cancer. PLoS One 7(11): E50266.
26. Lee DY, Deng Z, Wang CH, Yang BB (2007) MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci USA 104(51): 20350-20355.
27. Liu H, Zhu L, Liu B, Yang L, Meng X, Zhang W, Ma Y, Xiao H (2012) Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett 316(2): 196-203.
28. Livak K, Schmittgen T (2001) Analysis of relative gene expression data using real-Time quantitative PCR and the 2(-Delta Delta C(T). Methods 25(4): 402-408.
29. Mazeh H, Mizrahi I, Ilyayev N, Halle D, Brucher B, Bilchik A, Protic M, Daumer M, Stojadinovic A, Itzhak A, Nissan A (2013) The diagnostic and prognostic role of microRNA in colorectal cancer-A comprehensive review. J Cancer 4(3): 281-295.
30. McCulloch C, Searle S (2001) Generalized, Linear, and Mixed Models. Wiley Series in Probability and Statistics: New York, NY, USA.
31. McLoughlin RM, O'Morain CA (2006) Colorectal cancer screening. World J Gastroenterol 12(42): 6747-6750.
32. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T (2007) MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133(2): 647-658.
33. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105(30): 10513-10518.
34. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, Sung JJ (2009) Differential expression of microRNAs in plasma of patients with colorectal cancer: A potential marker for colorectal cancer screening. Gut 58(10): 1375-1381.
35. Perrone F, Lampis A, Bertan C, Verderio P, Ciniselli CM, Pizzamiglio S, Frattini M, Nucifora M, Molinari F, Gallino G, Gariboldi M, Meroni M, Leo E, Pierotti MA, Pilotti S (in press) Circulating Free DNA in a screening programme for early colorectal cancer detection. Tumori.
36. Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, Tait JF, Tewari M (2012) Blood cell origin of circulating microRNAs: A cautionary note for cancer biomarker studies. Cancer Prev Res (Phila) 5(3): 492-497.
37. Pu XX, Huang GL, Guo HQ, Guo CC, Li H, Ye S, Ling S, Jiang L, Tian Y, Lin TY (2010) Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol 25(10): 1674-1680.
38. Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R, Svoboda M, Vyzula R, Slaby O (2012) Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med 10: 55.
39. Reid JF, Sokolova V, Zoni E, Lampis A, Pizzamiglio S, Bertan C, Zanutto S, Perrone F, Camerini T, Gallino G, Verderio P, Leo E, Pilotti S, Gariboldi M, Pierotti MA (2012) miRNA profiling in colorectal cancer highlights miR-1 involvement in MET-dependent proliferation. Mol Cancer Res 10(4): 504-515.
40. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce CM, Harris CC (2008) MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299(4): 425-436.
41. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT (2011) MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13(4): 423-433.
42. Wang B, Zhang Q (2012) The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J Cancer Res Clin Oncol 138(10): 1659-1666.
43. Wang LG, Gu J (2012) Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiol 36(1): E61-e67.
44. Zhu S, Si ML, Wu H, Mo YY (2007) MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 282(19): 14328-14336.